ATAI Raises $125m Series C To Expand The Boundaries In Mental Health

Portfolio Includes Psychedelic And Non-Psychedelic Drugs

 
• By Alaric DeArment

The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.

Business, Technology, Internet and network concept. Young businessman working on a virtual screen of the future and sees the inscription: venture capital
ATAI Life Sciences raised $125m to fund preclinical and clinical mental health programs. • Source: Shutterstock

More from Clinical Trials

More from R&D